Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Generics Bulletin Originals

Set Alert for Originals
What's Next?

What’s Next? Five Things To Look Out For In September

Generics Bulletin previews the most notable and anticipated events for September 2023.

Biosimilars Generic Drugs

What’s Next? Five Things To Look Out For In August

Generics Bulletin previews the most notable and anticipated events for August 2023.

Biosimilars Generic Drugs

What’s Next? Five Things To Look Out For In July

Generics Bulletin previews the most notable and anticipated events for July 2023.

Biosimilars Generic Drugs

What’s Next? Five Things To Look Out For In June

Generics Bulletin previews the most notable and anticipated events for June 2023.

Biosimilars Generic Drugs
See All
Interviews

‘There Is Always Room For Improvement’: Celltrion Reflects On A Decade Of European Biosimilars

Marking a decade since Celltrion’s Remsima version of infliximab became the first monoclonal antibody biosimilar approved in Europe, Kevin Byoung Seo Choi, senior vice president and head of the marketing division at Celltrion Healthcare, talks to Generics Bulletin about the firm’s progress so far and the “room for improvement” that the company perceives in areas such as regulation, market access and pricing, supply chain and procurement – as well as what the future holds for the Korean biosimilars giant.

Biosimilars Europe

US FDA’s New Generics Chief: We Need More Flexibility For Complex Products

Iilun Murphy said Hatch-Waxman was written with immediate-release oral drugs in mind, not the complex generics becoming more popular today. The agency is evaluating the issue.

Generic Drugs FDA

Beyond Viatris: Kiran Mazumdar-Shaw Talks Next Steps For Biocon Biologics

As Biocon Biologics completes its integration of the biosimilars front-end business that it acquired from former partner Viatris, Biocon founder and chairperson Kiran Mazumdar-Shaw talks to Generics Bulletin about how the firm is now capturing the full value of its biosimilars, while also looking at expanding into new markets previously unserved by Viatris.

Biosimilars M & A

‘I Really Could Not Refuse’: Pharmascience CEO Arès Reflects On First Six Months

Taking over from the son of the company’s founder at the beginning of 2023, Martin Arès, the CEO of Canadian generics manufacturer Pharmascience, talks to Generics Bulletin about investment, international expansion and biosimilars.

Commercial Strategy
See All
Pricewatch UK

Betahistine Leads A Raft Of UK Rises In August

With multiple generic molecules experiencing treble-digit-percentage price increases in the UK in August, betahistine tablets led the month’s biggest risers, according to WaveData.

Market Intelligence Pricing Strategies

July Wholesaler Hike Sees UK Olanzapine Prices Spike

July brought UK price spikes for multiple presentations of generic olanzapine orodispersible tablets. Market researcher WaveData reveals the reason behind the increases.

Market Intelligence Pricing Strategies

Pantoprazole Leads Off UK Price Spikes In June

Amid triple-digit-percentage average price rises for several generic molecules in the UK during June 2023, pantoprazole topped the list.

Market Intelligence Pricing Strategies

UK Olanzapine Prices Rocket Up In May

Three presentations of olanzapine orodispersible tablets topped our table of the UK generics market’s Biggest Risers for May 2023.

Market Intelligence Pricing Strategies
See All
UsernamePublicRestriction

Register